Mus musculus Transcriptome of K-RAS-mutated lung adenocarcinoma
收藏NIAID Data Ecosystem2026-04-25 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP186214
下载链接
链接失效反馈官方服务：
资源简介：
Lung adenocarcinomas with oncogenic K-RAS mutations exhibit activation of JAK-STAT signaling. Pharmacological inhibition of JAK signaling using ruxolitinib significantly restrains tumor progression in preclinical models of K-RAS-driven lung cancer. Ruxolitinib is an FDA-approved drug routinely use in clinics, thus our results can be straightforward evaluated in a clinical trial.
创建时间：
2019-09-04
